815: Human Kallikrein 2 (HK2) Inhibitors Suppress Tumor Growth of Prostate Cancer Xenografts in Nude Mice

2006 ◽  
Vol 175 (4S) ◽  
pp. 263-263
Author(s):  
Christoph Kündig ◽  
Sylvain M. Cloutier ◽  
Steve Aellen ◽  
Loyse M. Felber ◽  
Jair R. Chagas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Growth ◽  
Nude Mice ◽  
Human Kallikrein 2 ◽  
Kallikrein 2

HUMAN KALLIKREIN 2 (HK2) INHIBITORS SUPPRESS TUMOUR GROWTH OF PROSTATE CANCER XENOGRAFTS IN NUDE MICE

2006 ◽  
Vol 5 (2) ◽  
pp. 163
Author(s):  
C. Kündig ◽  
S. Cloutier ◽  
S. Aellen ◽  
L. Felber ◽  
J. Chagas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Nude Mice ◽  
Tumour Growth ◽  
Human Kallikrein 2 ◽  
Kallikrein 2

scholarly journals Development of Sensitive Immunoassays for Free and Total Human Glandular Kallikrein 2

2004 ◽  
Vol 50 (9) ◽  
pp. 1607-1617 ◽  
Author(s):  
Ville Väisänen ◽  
Susann Eriksson ◽  
Kaisa K Ivaska ◽  
Hans Lilja ◽  
Martti Nurmi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Detection Limit ◽  
Solid Phase ◽  
Specific Antigen ◽  
Control Group ◽  
Serum Samples ◽  
Human Kallikrein 2 ◽  
Kallikrein 2 ◽  
Capture Antibody ◽  
Total Psa

Abstract Background: Free and total human kallikrein 2 (hK2) might improve the discrimination between prostate cancer and benign prostatic hyperplasia. Concentrations of hK2 are 100-fold lower than concentrations of prostate-specific antigen (PSA); therefore, an hK2 assay must have a low detection limit and good specificity. Methods: PSA- and hK2-specific monoclonal antibodies were used in solid-phase, two-site immunofluorometric assays to detect free and total hK2. The total hK2 assay used PSA-specific antibodies to block nonspecific signal. The capture antibody of the free hK2 assay did not cross-react with PSA. To determine the hK2 concentrations in the male bloodstream, total hK2 was measured in a control group consisting of 426 noncharacterized serum samples. Free and total hK2 were measured in plasma from 103 patients with confirmed prostate cancer. Results: All 426 males in the control group had a total hK2 concentration above the detection limit of 0.0008 μg/L. The median total hK2 concentration was 0.022 μg/L (range, 0.0015–0.37 μg/L). hK2 concentrations were 0.1–58% of total PSA (median, 3.6%). hK2 concentrations were similar in men 41–50 and 51–60 years of age. The ratio of hK2 to PSA steadily decreased from 5–30% at PSA <1 μg/L to 1–2% at higher PSA concentrations. In 103 patients with prostate cancer, the median hK2 concentration in plasma was 0.079 μg/L (range, 0.0015–16.2 μg/L). The median free hK2 concentration was 0.070 (range, 0.005–12.2) μg/L. The proportion of free to total hK2 varied from 17% to 131% (mean, 85%). Conclusions: The wide variation in the free-to-total hK2 ratio suggests that hK2 in blood plasma is not consistently in the free, noncomplexed form in patients with prostate cancer. The new assay is sufficiently sensitive to be used to study the diagnostic accuracies of free and total hK2 for prostate cancer.

The value of (−7, −5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer

2004 ◽  
Vol 93 (6) ◽  
pp. 720-724 ◽  
Author(s):  
C.H. Bangma ◽  
M.F. Wildhagen ◽  
G. Yurdakul ◽  
F.H. Schröder ◽  
B.G. Blijenberg
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Serum Markers ◽  
Human Kallikrein 2 ◽  
Kallikrein 2

scholarly journals Association of Polymorphism rs198977 in Human Kallikrein-2 Gene (KLK2) with Susceptibility of Prostate Cancer: A Meta-Analysis

PLoS ONE ◽  
2013 ◽  
Vol 8 (6) ◽  
pp. e65651
Author(s):  
Lishan Wang ◽  
Weidong Zang ◽  
Yunxia Sang ◽  
Dongli Xie ◽  
Li Wei ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Meta Analysis ◽  
Human Kallikrein 2 ◽  
Kallikrein 2

scholarly journals A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer

Sensors ◽  
2015 ◽  
Vol 15 (5) ◽  
pp. 11972-11987 ◽  
Author(s):  
Sang Lee ◽  
Kazuo Hosokawa ◽  
Soyoun Kim ◽  
Ok Jeong ◽  
Hans Lilja ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Porous Silicon ◽  
Accurate Diagnosis ◽  
Highly Sensitive ◽  
Human Kallikrein 2 ◽  
Kallikrein 2

700 TOTAL HUMAN KALLIKREIN 2 - A POTENTIALLY USEFUL SERUM MARKER OF BONE METASTASIS AND BIOCHEMICAL FAILURE IN PROSTATE CANCER

2009 ◽  
Vol 8 (4) ◽  
pp. 295 ◽  
Author(s):  
J. Phillips ◽  
C.L. Eaton ◽  
L. Proctor ◽  
D. Sokhi ◽  
A. Cronin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Serum Marker ◽  
Biochemical Failure ◽  
Human Kallikrein 2 ◽  
Kallikrein 2

Bradykinin-related compounds as new drugs for cancer and inflammation

2002 ◽  
Vol 80 (4) ◽  
pp. 275-280 ◽  
Author(s):  
John M Stewart ◽  
Lajos Gera ◽  
Daniel C Chan ◽  
Paul A Bunn Jr. ◽  
Eunice J York ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lung Cancer ◽  
Tumor Growth ◽  
Small Cell Lung Cancer ◽  
Nude Mice ◽  
Small Cell ◽  
Small Cell Lung ◽  
Related Compounds

Bradykinin (BK) (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) is an important growth factor for small-cell lung cancer (SCLC) and prostate cancer (PC). These cancers have cells of neuroendocrine origin and express receptors for a variety of neuropeptides. BK receptors are expressed on almost all lung cancer cell lines and on many PC cells. Our very potent BK antagonist B9430 (D-Arg-Arg-Pro-Hyp-Gly-Igl-Ser-D-Igl-Oic-Arg) (Hyp, trans-4-hydroxy-L-proline; Igl, α-2-indanylglycine; Oic, octahydroindole-2-carboxylic acid) is a candidate anti-inflammatory drug but does not inhibit growth of SCLC or PC. When B9430 is dimerized by N-terminal cross-linking with a suberimide linker, the product B9870 is a potent growth inhibitor for SCLC both in vitro and in vivo in athymic nude mice. Daily i.p. injection at 5 mg·kg–1·day–1 beginning on day 8 after SCLC SHP-77 cell implantation gave 65% inhibition of tumor growth. B9870 stimulates apoptosis in SCLC by a novel "biased agonist" action. We have also developed new small mimetic antagonists. BKM-570 (F5C-OC2Y-Atmp) (F5C, pentafluorocinnamic acid; OC2Y, O-2,6-dichlorobenzyl tyrosine; Atmp, 4-amino-2,2,6,6-tetramethylpiperidine) is very potent for inhibition of SHP-77 growth in nude mice. When injected daily i.p. at 5 mg·kg–1, M-570 gave 90% suppression of tumor growth. M-570 is more potent than the well-known anticancer drug cisPlatin (60% inhibition) or the recently developed SU5416 (40% inhibition) in this model. M-570 also showed activity against various other cancer cell lines in vitro (SCLC, non-SCLC, lung, prostate, colon, cervix) and inhibited growth of prostate cell line PC3 in nude mice. M-570 and related compounds evidently act in vivo through pathways other than BK receptors. These compounds have clinical potential for treatment of human lung and prostate cancers.Key words: bradykinin antagonists, cancer, inflammation, prostate cancer, small cell lung cancer.

Sign in / Sign up

Export Citation Format

Share Document